reports
- Christophe DOMBU
Biocorp could achieve decisive milestones in 2017
For the past 2 years, Biocorp has initiated major business transformations in order to become a key player in the booming market of connected health. The company has developed a range of connected devices addressing major healthcare issues. The company made significant advances in 2016 by signing 4 partnerships agreements with pharmaceutical players. Based on these agreements, Biocorp and its partners initiated preliminary studies assessing the feasibility and the performance of Biocorp’s con...
- Christophe DOMBU
Implanet’s Jazz sales up 18% in 2016
​ Implanet published its 2016 sales, confirming the good dynamics of its marketing activity (+18% compared to 2015, from €6.7 M to €7.8 M). The company benefits from the growing adoption of its lead product, the Jazz Band, especially in France and the US. Given the company’s efforts to further accelerate the adoption of Jazz, we believe that the company has the means to maintain this trend in 2017. Although the reported sales are slightly below our forecast, we remain confident on the co...
- Christophe DOMBU
Implanet confirms clinical benefits of Jazz implants after three years...
​Implanet released additional clinical data showing the good performance of the Jazz band implant in correcting large spine deformitiesinadolescents.Datawerepublishedinawhitepaper by French KOLs, giving Implanet additional arguments to convince more surgeons to adopt the company’s product, while expandingitsscopeofapplication.Implanet recently secured a € 6.9Mfollow-onfinancing.Theoperationreceivedastrongsupportfromseinstitutionalinvestorsdespitedifficultmarketconditions.The funds will sup...
- Christophe DOMBU
Biocorp announced a 23% increase of revenues for H1-2016 and a new par...
Biocorp is a medical device supplier for large pharmaceutical companies, and reported encouraging interim results. The company recorded a 23% increase of its revenue to €1.6 M, mainly attributedto sales on its historical activity. On the other hand, the company reported a 32% increase in operational expenses (€3.7 M), mainly due to investments made to support and anticipate the growthof the company’s business. Net loss for the first half of 2016 was €1.9 M, compared to €0.8 M as of Jun...
- Christophe DOMBU
Extended US patent protection for Quantum Genomics’ drug candidates
Quantum Genomics announced that the United States Patent and Trademark Office (USPTO) granted the Company two patents protecting its technology until 2031 and 2033. Quantum Genomics is specializing in cardiovascular diseases with first-in class drug candidates, Brain Aminopeptidase A inhibitors. The Company has also made important progress on its developmentplan. For instance, a Phase IIa trial in heart failure has just been authorized in France. The Company also completed QGC001 Phase IIa trial...
- Christophe DOMBU
Deuxième étude de phase 2a avec ABX464 dans le VIH
Abivax vient de recevoir l’aval des autorités réglementaires pour mener une étude de phase 2a en Europe, avec son produit ABX464 indiqué pour le traitement des infections au VIH. Cette étude intervient après la publication de résultats positifs d’une première étude de phase 2a établissant la première preuve d’efficacité de ce médicament first-in-class chez l’homme. La société compte ainsi renforcer l’attractivité de son produit phare en démontrant son potentiel pour la...
- Christophe DOMBU
Several collaborations with the line of connected devices
Nine months following its Initial public offering on the French stock market Alternext, Biocorp reported important progress with its portfolio of connected devices. The company announced several collaboration agreements with leading pharmaceutical players to develop Datapen and Easylog in the endocrinology and neurology fields. Although the company has yet to disclose more precisely for which indications they will be developed, this confirms the interest of pharmaceutical companies for Biocorpâ€...
- Christophe DOMBU
Biocorp announces collaborations in the endocrinology and neurology ...
​ Nine months following its Initial public offering on the French stock market Alternext, Biocorp reported important progress with its portfolio of connected devices. The company announced several collaboration agreements with leading pharmaceutical players to develop Datapen and Easylog in the endocrinology and neurology fields. Although the company has yet to disclose more precisely for which indications they will be developed, this confirms the interest of pharmaceutical companies for Bioco...
- Christophe DOMBU
€8.6M raised to fund programs in hypertension and heart failure
The French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases successfully closed a €8.6M private placement and follow-on offering from European and American investors. With the reinforcement of their cash position, the company should have a 2-year financial visibility, and will be able to further advance its research programs. Quantum Genomics is developing centrally active first-in-class drugs, the Brain aminopeptidases Inhibitors (BAPAIs), with p...
Merger with Effimune to become a leader in immunotherapy
OSE Pharma announced its proposed merger with privately-held biotechnology company Effimune, which specializes in the development of treatments for auto-immune diseases and for cancer. The combined entity, to be named OSE Immunotherapeutics, will have a well-balanced pipeline of drug candidates whose mechanism of action relies on the activation and/or modulation of the immune system, giving the new company, a strong position in immunotherapy. The lead programs of OSE Immunotherapeutics, whose ma...
- Christophe DOMBU
Proprietary products to drive Diaxonhit’s growth in 2016
Diaxonhit is a company developing, producing, and marketing in vitro diagnostic (IVD) tests. Diaxonhit’s expertise in IVD development resides in genomics and proteomics technologies. The company has a dual business model comprised of the distribution of a wide range of IVD tests in France, Belgium and Switzerland through its Ingen subsidiary, and with the development of innovative IVD tests. The company has generated a well-balanced portfolio of proprietary products and licensed IVD tests (Fig...
Première preuve d’efficacité d’ABX464 contre le VIH chez l’hom...
Abivax vient d’annoncer les résultats positifs de l’étude de phase 2a avec son candidat médicament ABX464 indiqué contre le VIH. Ces résultats montrent la bonne tolérance du médicament en monothérapie chez les patients infectés au VIH, ainsi qu’un effet dose-dépendant, sur la réduction de la charge virale. Par ailleurs, ces données établissent pour la première fois, la preuve d’efficacité d’ABX464 sur des malades et confirment l’intérêt de ce nouveau médicament po...
- Christophe DOMBU
2016, a decisive year for Quantum Genomics
Quantum Genomics develops cutting edge drugs (Brain Amino- Peptidase Inhibitors, BAPAIs) for cardiovascular diseases, with unmet medical needs, and more specifically, resistant hypertension and heart failure. The company just announced it successfully completed the recruitment of the Phase 2a trial for QGC001, a first-in-class drug candidate for the treatment of hypertension. Preliminary results are expected in Q3-2016, ahead of schedule, and could provide the first proof of efficacy for BAPAIs ...
- Christophe DOMBU
2016, a decisive year for Quantum Genomics
Quantum Genomics develops cutting edge drugs (Brain Amino- Peptidase Inhibitors, BAPAIs) for cardiovascular diseases, with unmet medical needs, and more specifically, resistant hypertension and heart failure. The company just announced it successfully completed the recruitment of the Phase 2a trial for QGC001, a first-in-class drug candidate for the treatment of hypertension. Preliminary results are expected in Q3-2016, ahead of schedule, and could provide the first proof of efficacy for BAPAIs ...
- Christophe DOMBU
First positive DSMB with QGC001 in hypertension
Quantum Genomics, a French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases, received the first positive recommendation from the Data Safety Monitoring Board (DSMB) to continue QGC001’s phase 2a trial in hypertension. QGC001 is a first-in-class drug candidate addressing resistant hypertension, a serious condition affecting 100 to 150 million people worldwide, for which there is currently no effective drug. According to the World Health Organizatio...
gets first positive DSMB with QGC001 in hypertension
Quantum Genomics, a French biopharmaceutical company developing cutting-edge drugs in the field of cardiovascular diseases, received the first positive recommendation from the Data Safety Monitoring Board (DSMB) to continue QGC001's phase 2a trial in hypertension. QGC001 is a first-in-class drug candidate addressing resistant hypertension, a serious condition affecting 100 to 150 million people worldwide, for which there is currently no effective drug. According to the World Health Organization,...
Beleodaq and Livatag, orphan drugs with blockbuster potential?
Onxeo is a company specializing in orphan drug oncology and currently has 3 products in late stage development. The orphan drug market, which is expected to grow to $176B by 2020 with a 2014-2020 CAGR of +10.5%, has attracted numerous biopharmaceutical companies seeking to get a share of this lucrative market. Despite the limited number of patients in orphan indications, the potential is huge as demonstrated by some orphan drugs that have become blockbuster drugs, generating more than $1 billio...
Biocorp strengthens its portfolio of connected insulin pens with Easyl...
Biocorp Production, a French medical device supplier for large pharmaceutical companies, announced the launch of a new connected medical device, Easylog, intended to improve quality of life and treatment compliance for diabetic patients using insulin pens. Insulin pens are the most common insulin injection devices, already used by more than 50 million diabetic patients worldwide. According to Renhub Research, the 2014 insulin pen market was estimated at $10 billion, largely dominated by Novo Nor...
Fin de recrutement de la phase 2b/3 pour ABX203 dans l’hépatite B
Abivax a annoncé la fin du recrutement des patients dans l'étude de Phase 2b/3 avec son candidat ABX203 dans l'hépatite B chronique.Pour cette maladie sévère qui touche plus de 350 millions de personnes, il n'existe aucun traitement curatif. L'offre thérapeutique actuelle est limitée et extrêmement contraignante car nécessite une prise du médicament quotidienne et à vie. Cette information est conforme à notre modèle de valorisation de la société Abivax. Nous maintenons ainsi notre...
Biocorp, se connecter pour mieux se soigner
​Biocorp, acteur de la santé connectée, s'inscrit depuis 2004 dans la chaîne de valeur des entreprises pharmaceutiques. Biocorp développe, produit et commercialise des dispositifs médicaux dont la génération la plus récente s'adresse au nouveau marché de l'e-santé. Nous initions la couverture de Biocorp avec un objectif de 17,59€/action, soit une capitalisation boursière estimée à 52,03M€. Cette valorisation a été effectuée sur la base de son activité historique dans l'inj...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.